Table 2. 200% ProMACE-CytaBOM... | American Society of Hematology

Table 2.

200% ProMACE-CytaBOM

Cyclophosphamide

1300 mg/m², day 1

Doxorubicin^*

50 mg/m², day 1

Etoposide

240 mg/m², day 1

Prednisone

60 mg/m² PO, days 1-14

Cytarabine

600 mg/m², day 8

Bleomycin

5 mg/m², day 8

Vincristine^†

1.4 mg/m², day 8

Methotrexate

120 mg/m², day 8

Leucovorin

25 mg/m² PO every 6 hours for four doses to begin 24 hours after Methotrexate

Plus

rH-GM-CSF^‡ or

5 μg/kg/day SC days 9 to 19

rH-G-CSF^2-153

5 μg/kg/day SC days 9 to 19

Dose Modifications^2-155
ANC	Methotrexate	Ara-C	Cyclo- phosphamide	Doxo- rubicin	VP-16
≥1,500	100%	100%	100%	100%	100%
1,500 to 1,999	100%	100%	100%	100%	100%
1,000 to 1,499	100%	75%	50%	50%	50%
500 to 999	100%	25%	25%	25%	25%
<500	50%	Hold	Hold	Hold	Hold
Platelets	Methotrexate	Ara-C	Cyclo- phosphamide	Doxo- rubicin	VP-16
≥100,000	100%	100%	100%	100%	100%
50,000 to 99,999	100%	50%	75%	75%	50%
<50,000	50%	Hold	Hold	Hold	Hold

Dose Modifications^2-155
ANC	Methotrexate	Ara-C	Cyclo- phosphamide	Doxo- rubicin	VP-16
≥1,500	100%	100%	100%	100%	100%
1,500 to 1,999	100%	100%	100%	100%	100%
1,000 to 1,499	100%	75%	50%	50%	50%
500 to 999	100%	25%	25%	25%	25%
<500	50%	Hold	Hold	Hold	Hold
Platelets	Methotrexate	Ara-C	Cyclo- phosphamide	Doxo- rubicin	VP-16
≥100,000	100%	100%	100%	100%	100%
50,000 to 99,999	100%	50%	75%	75%	50%
<50,000	50%	Hold	Hold	Hold	Hold

Total dose not to exceed 550 mg/m².

Cap = 2 mg.

n = 46.

n = 28.

Modification based on ANC and platelet count on day of treatment.